Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$56.27 - $73.77 $372,845 - $488,800
6,626 New
6,626 $457,000
Q1 2023

May 15, 2023

BUY
$47.19 - $70.77 $1 Million - $1.5 Million
21,243 Added 24.47%
108,057 $7.33 Million
Q4 2022

Feb 14, 2023

BUY
$30.35 - $53.15 $101,551 - $177,839
3,346 Added 4.01%
86,814 $4.3 Million
Q3 2022

Nov 14, 2022

SELL
$31.97 - $49.37 $1.05 Million - $1.63 Million
-32,992 Reduced 28.33%
83,468 $2.71 Million
Q2 2022

Aug 15, 2022

SELL
$35.61 - $76.23 $204,721 - $438,246
-5,749 Reduced 4.7%
116,460 $4.59 Million
Q1 2022

May 16, 2022

SELL
$57.56 - $82.54 $3.22 Million - $4.62 Million
-55,939 Reduced 31.4%
122,209 $8.55 Million
Q4 2021

Feb 14, 2022

SELL
$72.5 - $100.68 $8.2 Million - $11.4 Million
-113,153 Reduced 38.84%
178,148 $13.9 Million
Q3 2021

Nov 12, 2021

BUY
$90.24 - $124.05 $1.3 Million - $1.78 Million
14,380 Added 5.19%
291,301 $27.8 Million
Q2 2021

Aug 13, 2021

BUY
$93.66 - $139.27 $5.84 Million - $8.68 Million
62,311 Added 29.03%
276,921 $34.4 Million
Q1 2021

May 17, 2021

BUY
$116.57 - $155.01 $16.9 Million - $22.4 Million
144,610 Added 206.59%
214,610 $28.3 Million
Q4 2020

Feb 16, 2021

SELL
$99.61 - $142.12 $3.98 Million - $5.68 Million
-40,000 Reduced 36.36%
70,000 $9.27 Million
Q3 2020

Nov 16, 2020

BUY
$72.92 - $102.01 $1.46 Million - $2.04 Million
20,000 Added 22.22%
110,000 $11.2 Million
Q2 2020

Aug 14, 2020

BUY
$55.75 - $92.75 $5.02 Million - $8.35 Million
90,000 New
90,000 $7.83 Million

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $10.2B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Lombard Odier Asset Management (Switzerland) Sa Portfolio

Follow Lombard Odier Asset Management (Switzerland) Sa and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lombard Odier Asset Management (Switzerland) Sa, based on Form 13F filings with the SEC.

News

Stay updated on Lombard Odier Asset Management (Switzerland) Sa with notifications on news.